COVID-19
As of June 29, there were 13 vaccines against COVID-19 in human clinical trials.
In a forthcoming paper, 239 scientists from more than 30 countries are pushing the World Health Organization to pay more attention to the possible airborne spread of SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
It’s not clear how long the trial will be delayed, but according to a report by STAT, it may still begin in July.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
Moderna has always been an odd and secretive company. Currently all eyes are on the company because it is the furthest along in developing a vaccine against COVID-19.
The “printers” are portable, automated messenger RNA (mRNA) production units, which Elon Musk referred to as “RNA microfactories.”
PRESS RELEASES